Amyotrophic Lateral Sclerosis Clinical Trials in Georgia

A listing of Amyotrophic Lateral Sclerosis clinical trials in Georgia actively recruiting patient volunteers.

Home

All Clinical Trials

Georgia

Amyotrophic Lateral Sclerosis

1 - 7 of 7

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

CMV Vaccine Trial For Young Women Ages 16-17

Recruiting

A Cytomegalovirus (CMV) Investigational Vaccine Clinical Trial for Healthy Women Age 16 to 17 years old. Compensation included.

Conditions:

Healthy Volunteers

Healthy

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Paid Vaccine Study For Teens

Recruiting

Vaccine study that aims to protect teens ages 12–17 against Epstein-Barr virus (EBV) and infectious mononucleosis (mono).

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Adult Migraine Study

Recruiting

Migraine study for adults. You may be compensated up to $800 for your time and travel expenses.

Conditions:

Headache

Cluster Headache

Headache Disorders

Post-Traumatic Headache

Migraine

Menstrual Migraine

Classic Migraine

Migraine

With or Without Aura

Learn More

* Compensation for time may be available

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

NCT04494256

Recruiting

The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS). The ALSpire Study consists of two parts: Part 1: 6-month placebo-controlled study. During Part 1, participants are randomly assigned to receive either BIIB105 or placebo in a 3:1 or 2:1 ratio (depending on the participant's assigned Cohort). Part 2: 2-year long-term open-label extension. During Part 2, all participants receive BIIB105. The objectives of... Read More

Gender:

All

Ages:

18 years and above

Locations: The Emory Clinic, Atlanta, Georgia +16 locations

Conditions: Amyotrophic Lateral Sclerosis

Learn More ›

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898

Recruiting

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

Gender:

All

Ages:

Between 18 years and 80 years

Locations: Augusta University, Augusta, Georgia +23 locations

University of California, Orange, California

Mayo Clinic, Jacksonville, Florida

Augusta University, Augusta, Georgia

Indiana University IU Health Neuroscience Center, Indianapolis, Indiana

University of Kansas Medical Center, Kansas City, Kansas

Johns Hopkins University, Baltimore, Maryland

Hennepin Healthcare Research Institute, Minneapolis, Minnesota

Mayo Clinic / Rochester, Rochester, Minnesota

Hospital for Special Surgery, New York, New York

SUNY Upstate Medical University, Syracuse, New York

Atrium Health Neurosciences Institute, Charlotte, North Carolina

Duke University, Durham, North Carolina

Providence Brain and Spine Institute, Portland, Oregon

Lehigh Valley Health Network, Allentown, Pennsylvania

Allegheny Health Network, Allegheny Neurological Associates, Pittsburgh, Pennsylvania

University of Virginia Health System, Charlottesville, Virginia

Swedish Neuroscience Institute, Seattle, Washington

University of Alberta Hospital, Edmonton, Alberta

McMaster University Medical Center, Hamilton, Ontario

Sunnybrook Research Institute, Toronto, Ontario

Montreal Neurological Institute and Hospital, Montreal, Quebec

Clinique Maladies Neuromusculaire, Sherbrooke, Quebec

University of Saskatchewan - Sastakoon Hospital, Saskatoon, Saskatchwean

Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval, Quebec, Not set

Conditions: Amyotrophic Lateral Sclerosis

Learn More ›

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

NCT05349721

Recruiting

This study will assess the effects and safety of PTC857 treatment in participants diagnosed with ALS.

Gender:

All

Ages:

Between 18 years and 80 years

Locations: Augusta University, Augusta, Georgia +21 locations

UC Irvine Health ALS and Neuromuscular Center, Orange, California

Forbes Norris MDA/ALS Research Center at California Pacific Medical Center, San Francisco, California

Phil Smith Neuroscience Institute, Holy Cross Hospital, Fort Lauderdale, Florida

Intercoastal Medical Group, Inc., Sarasota, Florida

University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida

Augusta University, Augusta, Georgia

University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City, Kansas

Henry Ford Health System Department of Neurology, Detroit, Michigan

Neurology Associates, P.C. / Somnos Clinical Research, Lincoln, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Lewis Katz School of Medicine at Temple Universtiy, Philadelphia, Pennsylvania

National Neuromuscular Research Institute, Austin, Texas

Nerve and Muscle Center of Texas, Houston, Texas

Royal Brisbane and Women's Hospital, Brisbane, Queensland

Austin Health, Heidelberg, Victoria

CHU de Bordeaux, Bordeaux Cedex, Not set

Hôpital Neurologique Pierre Wertheimer, Bron Cedex, Not set

CHRU Lille - Hôpital Roger Salengro, Lille Cedex, Not set

CHU Dupuytren 1 Limoges, Limoges, Not set

Centrum Medyczne Neuro Protect, Warszawa, Not set

Hospital Universitario Vall d'Hebron ALS Unit., Barcelona, Not set

Hospital Universitario y Politecnico La Fe, Valencia, Not set

Conditions: Amyotrophic Lateral Sclerosis

Learn More ›

HEALEY ALS Platform Trial - Master Protocol

NCT04297683

Recruiting

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Gender:

All

Ages:

18 years and above

Locations: Emory University, Atlanta, Georgia +67 locations

Barrow Neurological Institute, Phoenix, Arizona

Loma Linda University Health, Loma Linda, California

University of Southern California, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

University of California, Irvine, Orange, California

Forbes Norris MDA/ALS Research Center, California Pacific Medical Center, San Francisco, California

University of California, San Francisco, San Francisco, California

University of Colorado, Aurora, Colorado

Hospital for Special Care, New Britain, Connecticut

Georgetown University, Washington, District of Columbia

George Washington University, Washington, District of Columbia

Nova Southeastern University, Davie, Florida

Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale, Florida

University of Florida, Gainesville, Florida

Mayo Clinic Florida, Jacksonville, Florida

University of Miami, Miami, Florida

University of South Florida, Tampa, Florida

Emory University, Atlanta, Georgia

Augusta University, Augusta, Georgia

Saint Alphonsus Regional Medical Center, Boise, Idaho

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University Health, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

University of Kansas Medical Center, Fairway, Kansas

University of Kentucky, Lexington, Kentucky

Ochsner Health System, New Orleans, Louisiana

University of Maryland, Baltimore, Maryland

Johns Hopkins University, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Massachusetts Medical School, North Worcester, Massachusetts

University of Michigan, Ann Arbor, Michigan

Henry Ford Health System, Detroit, Michigan

Spectrum Health, Grand Rapids, Michigan

Essentia Health, Duluth, Minnesota

University of Minnesota/Twin Cities ALS Research Consortium, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

University of Missouri Health Care, Columbia, Missouri

Saint Louis University, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Neurology Associates, P.C./Somnos Clinical Research, Lincoln, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Las Vegas Clinic, Las Vegas, Nevada

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Columbia University, New York, New York

SUNY Upstate, Syracuse, New York

Duke University, Durham, North Carolina

Wake Forest Health Science, Winston-Salem, North Carolina

University of Cincinnati, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Providence Brain and Spine Institute ALS Center, Portland, Oregon

Lehigh Valley Health Network, Allentown, Pennsylvania

Penn State Hershey, Hershey, Pennsylvania

Jefferson Weinberg ALS Center, Thomas Jefferson University, Philadelphia, Pennsylvania

University of Penn, Philadelphia, Pennsylvania

Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

University of Pittsburg Medical Center, Pittsburgh, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Neurology, Dallas, Texas

Houston Methodist, Houston, Texas

UTHSCSA, San Antonio, Texas

University of Utah, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Swedish Medical Center, Seattle, Washington

University of Washington, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Amyotrophic Lateral Sclerosis

Learn More ›

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684

Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Gender:

All

Ages:

18 years and above

Locations: Emory University, Atlanta, Georgia +25 locations

University of Alabama Birmingham, Birmingham, Alabama

University of California, Los Angeles, Los Angeles, California

University of California, San Diego, San Diego, California

University of California San Francisco, San Francisco, California

University of Colorado Denver, Denver, Colorado

Mayo Clinic Florida, Jacksonville, Florida

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Johns Hopkins University, Baltimore, Maryland

NIH, Bethesda, Maryland

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Washinton University in St. Louis, Saint Louis, Missouri

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada

Columbia Unversity, New York, New York

University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

Case Western Reserve Medical Center, Cleveland, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University, Nashville, Tennessee

Nantz National Alzheimer Center Houston, Houston, Texas

UT San Antonio Health Science Center, San Antonio, Texas

University of Washington, Seattle, Washington

University of British Columbia, Vancouver, British Columbia

University of Toronto, Toronto, Ontario

Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy

Learn More ›

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041

Recruiting

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

Gender:

All

Ages:

Between 18 years and 80 years

Locations: Emory University School of Medicine, Atlanta, Georgia +4 locations

Conditions: Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy

Learn More ›

The National Amyotrophic Lateral Sclerosis Registry

NCT01772602

Recruiting

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other... Read More

Gender:

All

Ages:

18 years and above

Locations: CDC, Atlanta, Georgia

Conditions: Amyotrophic Lateral Sclerosis

Learn More ›

1 - 7 of 7

Browse by Amyotrophic Lateral Sclerosis Clinical Trials by City

Amyotrophic Lateral Sclerosis clinical trials in Atlanta

Amyotrophic Lateral Sclerosis clinical trials in Augusta